Akero Therapeutics Inc
Change company Symbol lookup
Select an option...
AKRO Akero Therapeutics Inc
GOL Gol Linhas Aereas Inteligentes SA
AAPL Apple Inc
JPM-L JPMorgan Chase & Co
BZFDW BuzzFeed Equity Warrant Exp 1st Dec 2026 *W EXP 12/01/2026
PANW Palo Alto Networks Inc
SIEGY Siemens AG
SLGL Sol Gel Technologies Ltd
AYRWF Ayr Wellness Inc
CTV Innovid Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Akero Therapeutics Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is a hormone that protects against cellular stress and regulates the metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase IIb clinical trials in patients with biopsy-confirmed NASH: the study in pre-cirrhotic patients with F2-F3 fibrosis and the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Its EFX program is focused on patients with cirrhotic NASH (F4, compensated) in Phase IIb clinical trial.

Postmarket

Last Trade
Delayed
$49.25
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$49.25
Day's Change
1.60 (3.36%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
50.63
Day's Low
48.55
Volume
(Average)
Volume:
583,028

10-day average volume:
545,695
583,028

Company Profile

Akero Therapeutics Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is a hormone that protects against cellular stress and regulates the metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase IIb clinical trials in patients with biopsy-confirmed NASH: the study in pre-cirrhotic patients with F2-F3 fibrosis and the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Its EFX program is focused on patients with cirrhotic NASH (F4, compensated) in Phase IIb clinical trial.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
6.47x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

January 2023
Current Month
4.2M
Previous Month
5.3M
Percent of Float
9.98%
Days to Cover
5.2471 Days

Share Information

AKRO is in a share class of common stock
Float
42.4M
Shares Outstanding
46.8M
Institutions Holding Shares
196
95.70%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Mark T. Iwicki
  • Andrew ChengPres.
  • Jonathan Young
  • Timothy Rolph
  • William WhiteCFO

Address

  • 601 Gateway Boulevard, Suite 350
  • South San Francisco, CA 94080
  • Phone: (650) 487-6488
  • Fax: (302) 655-5049
  • https://www.akerotx.com/

Insider Trading

During the most recent quarter, 2M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.